Can a simple protein infusion prevent deadly Re-Bleeding in cirrhosis patients?

NCT ID NCT07395141

Not yet recruiting Disease control Sponsor: King George's Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding albumin to standard treatment reduces re-bleeding and death in adults with cirrhosis who have acute variceal bleeding. Sixty participants will be randomly assigned to receive either albumin for three days plus standard care, or standard care alone. The main outcomes are re-bleeding during hospitalization and at six weeks, as well as in-hospital mortality.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Albumin
What this could lead to: If it works, this could show that adding albumin to standard treatment helps prevent re-bleeding and improves survival in people with cirrhosis and acute variceal bleeding.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Albumin is generally safe, but it may not provide significant benefit over standard care alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE VARICEAL BLEEDING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver esophageal varices with bleeding Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE VARICEAL BLEEDING CIRRHOSIS

Contacts and locations

Locations

Dr Sumit Rungta

Lucknow, Uttar Pradesh, 206003, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.